Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Casanova MJ, Nantes Ó, Varela P, Vela-González M, Rivero M, Sierra-Gabarda O, Riestra S, Barreiro-de Acosta M, Martín-Rodríguez MDM, Gargallo-Puyuelo CJ, Reygosa C, Muñoz R, de la Filia-Molina IG, Núñez-Ortiz A, Kolle L, Calafat M, Huguet JM, Iglesias-Flores E, Martínez-Pérez TJ, Bosch O, Duque-Alcorta JM, Frago-Larramona S, Van Domselaar M, González-Cosano VM, Bujanda L, Rubio S, Mancebo A, Castro B, García-López S, de Francisco R, Nieto-García L, Laredo V, Gutiérrez-Casbas A, Mesonero F, Leo-Carnerero E, Cañete F, Ruiz L, Gros B, Del Moral-Martínez M, Rodríguez C, Chaparro M, Gisbert JP.
Casanova MJ, et al. Among authors: sierra gabarda o.
Aliment Pharmacol Ther. 2023 Jul;58(1):60-70. doi: 10.1111/apt.17525. Epub 2023 Apr 23.
Aliment Pharmacol Ther. 2023.
PMID: 37089065